About OvaScience (NASDAQ:OVAS)
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation.
Industry, Sector and Symbol
Trailing P/E Ratio-0.622447552447552
Forward P/E RatioN/A
Sales & Book Value
Price / Sales109.62
Price / CashN/A
Book Value$1.80 per share
Price / Book0.49
Return on Equity-60.06%
Return on Assets-52.85%
OvaScience (NASDAQ:OVAS) Frequently Asked Questions
What is OvaScience's stock symbol?
OvaScience trades on the NASDAQ under the ticker symbol "OVAS."
How were OvaScience's earnings last quarter?
OvaScience Inc (NASDAQ:OVAS) released its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.62) by $0.08. The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. OvaScience had a negative net margin of 17,338.78% and a negative return on equity of 60.06%. The firm's revenue was down 73.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.66) earnings per share. View OvaScience's Earnings History.
When will OvaScience make its next earnings announcement?
Where is OvaScience's stock going? Where will OvaScience's stock price be in 2018?
3 analysts have issued 1 year price objectives for OvaScience's stock. Their predictions range from $1.00 to $15.00. On average, they expect OvaScience's share price to reach $8.00 in the next twelve months. View Analyst Ratings for OvaScience.
What are Wall Street analysts saying about OvaScience stock?
Here are some recent quotes from research analysts about OvaScience stock:
- 1. HC Wainwright analysts commented, "Refocus on Science Should Aid in the Long Term; Reit Buy Incremental progress as the company seeks to capitalize upon its internal expertise in cell biology. On yesterday’s 4Q17 call, the company provided an update on the OvaPrime and OvaTure programs as management pivoted to a R&D-focused strategy. We think the key takeaways are two-fold: (1) the interim data from the first 20 patients in the Phase 1 trial of OvaPrime appear to deliver bittersweet news. The safety data look clean, but no strong signals were observed on the secondary endpoints that could suggest efficacy. As a result, this trial has terminated patient enrollment, and per management, the company will advance OvaPrime directly to a Phase 1b/2a study in 2H18 with an improved cell processing technique to hopefully improve efficacy." (3/16/2018)
- 2. According to Zacks Investment Research, "OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. " (1/11/2018)
Who are some of OvaScience's key competitors?
Some companies that are related to OvaScience include Sophiris Bio (SPHS), Brainstorm Cell Therapeutics (BCLI), Opiant Pharmaceuticals (OPNT), Versartis (VSAR), Aptevo Therapeutics (APVO), Arcturus Therapeutics (ARCT), Caladrius Biosciences (CLBS), Catabasis Pharmaceuticals (CATB), Novus Therapeutics (NVUS), PLx Pharma (PLXP), Cardiome Pharma (CRME), pSivida (PSDV), CytRx (CYTR), TRACON Pharmaceuticals (TCON), IntelGenx Technologies (IGXT), Pain Therapeutics (PTIE), VIVUS (VVUS) and Immutep (IMMP).
Who are OvaScience's key executives?
OvaScience's management team includes the folowing people:
- Christopher A. Kroeger M.D., Chief Executive Officer
- Jonathan Gillis, principal Financial Officer, principal Accounting Officer, Vice President
- Karen Long, Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance
- James Luterman Ph.D., Executive Vice President - Research and Development
- Theresa McNeely, Executive Vice President, Chief Communications Officer (Age 51)
- James Lillie, Chief Scientific Officer
- Ravi Mehrotra Ph.D., Chief Corporate Development Officer
- Richard H. Aldrich, Lead Independent Director (Age 62)
- John P. Howe III M.D., Director (Age 67)
- John E. Sexton Ph.D., Director
Has OvaScience been receiving favorable news coverage?
Headlines about OVAS stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OvaScience earned a coverage optimism score of 0.04 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are OvaScience's major shareholders?
OvaScience's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.19%), Deutsche Bank AG (1.45%), Millennium Management LLC (0.81%) and Two Sigma Investments LP (0.68%). Company insiders that own OvaScience stock include Michelle Dipp, Paul WD Chapman and Richard Aldrich. View Institutional Ownership Trends for OvaScience.
Which major investors are selling OvaScience stock?
Which major investors are buying OvaScience stock?
OVAS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG and Two Sigma Investments LP. Company insiders that have bought OvaScience stock in the last two years include Michelle Dipp, Paul WD Chapman and Richard Aldrich. View Insider Buying and Selling for OvaScience.
How do I buy shares of OvaScience?
Shares of OVAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OvaScience's stock price today?
One share of OVAS stock can currently be purchased for approximately $0.89.
How big of a company is OvaScience?
OvaScience has a market capitalization of $31.98 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-50,970,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. OvaScience employs 118 workers across the globe.
How can I contact OvaScience?
OvaScience's mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 617-500-2802 or via email at [email protected]
MarketBeat Community Rating for OvaScience (OVAS)MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
OvaScience (NASDAQ:OVAS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.00||2.00||2.00||2.00|
|Ratings Breakdown: ||1 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$8.00||$8.00||$8.00||$8.00|
|Price Target Upside: ||798.88% upside||429.80% upside||429.80% upside||379.04% upside|
OvaScience (NASDAQ:OVAS) Consensus Price Target History
OvaScience (NASDAQ:OVAS) Analyst Ratings History
(Data available from 3/21/2016 forward)
OvaScience (NASDAQ:OVAS) Earnings History and Estimates Chart
OvaScience (NASDAQ OVAS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/8/2018|| || || || || || || || |
|11/2/2017||Q3 2017||($0.40)||($0.25)||$0.09 million||$0.06 million||View||N/A|
|8/3/2017||Q2 2017||($0.47)||($0.45)||$0.09 million||$0.08 million||View||Listen|
|5/9/2017||Q1 2017||($0.46)||($0.38)||$0.12 million||$0.06 million||View||Listen|
|3/2/2017||Q4 2016||($0.58)||($0.64)||$0.11 million||$0.12 million||View||Listen|
|11/3/2016||Q316||($0.62)||($0.54)||$0.25 million||$0.02 million||View||Listen|
|8/4/2016||Q216||($0.78)||($0.62)||$0.21 million||$0.19 million||View||Listen|
|5/5/2016||Q116||($0.72)||($0.80)||$0.14 million||$0.15 million||View||Listen|
|2/25/2016||Q315||($0.71)||($0.76)||$0.20 million||$0.16 million||View||Listen|
|11/5/2015||Q3||($0.68)||($0.66)||$0.17 million||$0.08 million||View||N/A|
|8/10/2015||Q215||($0.64)||($0.64)||$0.57 million||$0.03 million||View||N/A|
|5/11/2015||($0.65)||($0.65)||$0.40 million||$0.02 million||View||N/A|
OvaScience (NASDAQ:OVAS) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.21 EPS
Dividend History for OvaScience (NASDAQ:OVAS)
No dividend announcements for this company have been tracked by MarketBeat.com
OvaScience (NASDAQ OVAS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.50%
Institutional Ownership Percentage: 43.79%
OvaScience (NASDAQ OVAS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/1/2016||Michelle Dipp||CEO||Buy||425,000||$7.00||$2,975,000.00||971,921|| |
|5/18/2016||Michelle Dipp||CEO||Buy||20,000||$7.86||$157,200.00||971,921|| |
|5/17/2016||Michelle Dipp||CEO||Buy||40,000||$7.63||$305,200.00||971,921|| |
|5/13/2016||Richard Aldrich||Director||Buy||36,095||$6.94||$250,499.30||604,185|| |
|5/11/2016||Richard Aldrich||Director||Buy||20,000||$7.64||$152,800.00||604,185|| |
|5/10/2016||Michelle Dipp||CEO||Buy||19,900||$7.72||$153,628.00||971,921|| |
|5/10/2016||Paul W.D. Chapman||COO||Buy||3,100||$7.37||$22,847.00||3,100|| |
|3/24/2016||Michelle Dipp||CEO||Buy||59,800||$9.49||$567,502.00||971,921|| |
|3/22/2016||Michelle Dipp||CEO||Buy||59,800||$10.44||$624,312.00||971,921|| |
|3/18/2016||Michelle Dipp||CEO||Buy||59,700||$8.26||$493,122.00||971,921|| |
|3/16/2016||Michelle Dipp||CEO||Buy||59,029||$7.90||$466,329.10||971,921|| |
|3/14/2016||Michelle Dipp||CEO||Buy||162,732||$7.60||$1,236,763.20||971,921|| |
|10/5/2015||Jeffrey E Young||CFO||Buy||3,450||$10.70||$36,915.00||3,750|| |
|10/5/2015||Marc D Kozin||Director||Buy||4,800||$10.79||$51,792.00||20,553|| |
|9/9/2015||Mary Fisher||Director||Buy||6,100||$16.49||$100,589.00||6,415|| |
|9/8/2015||Marc D Kozin||Director||Buy||3,000||$17.60||$52,800.00||14,612|| |
|4/8/2015||Marc D Kozin||Director||Buy||3,000||$28.45||$85,350.00|| |
|4/2/2015||Michelle Dipp||CEO||Buy||1,000||$32.49||$32,490.00|| |
|1/13/2015||Thomas Malley||Director||Buy||35,000||$50.00||$1,750,000.00|| |
|7/7/2014||Richard Aldrich||Director||Buy||2,000||$9.49||$18,980.00|| |
|6/30/2014||Richard Aldrich||Director||Buy||2,000||$9.16||$18,320.00|| |
|6/23/2014||Richard Aldrich||Director||Buy||2,000||$8.81||$17,620.00|| |
|6/16/2014||Richard Aldrich||Director||Buy||2,000||$8.52||$17,040.00|| |
|6/9/2014||Richard Aldrich||Director||Buy||2,000||$7.59||$15,180.00|| |
|6/3/2014||Harald F Stock||Director||Buy||1,063||$7.01||$7,451.63|| |
|6/2/2014||Richard Aldrich||Director||Buy||2,000||$7.29||$14,580.00|| |
|5/27/2014||Richard Aldrich||Director||Buy||2,000||$7.50||$15,000.00|| |
|5/20/2014||Harald F Stock||Director||Buy||1,050||$7.13||$7,486.50|| |
|5/19/2014||Richard Aldrich||Director||Buy||2,000||$7.33||$14,660.00|| |
|3/7/2014||Fund L.P. Longwood||Major Shareholder||Buy||100,000||$10.00||$1,000,000.00|| |
|9/12/2013||Arthur Tzianabos||Insider||Buy||1,000||$10.32||$10,320.00|| |
|9/12/2013||Harald F Stock||Director||Buy||4,500||$10.64||$47,880.00|| |
|9/11/2013||Christopher A Bleck||Insider||Buy||2,000||$11.15||$22,300.00|| |
|9/11/2013||Richard Aldrich||Director||Buy||4,850||$10.54||$51,119.00|| |
OvaScience (NASDAQ OVAS) News Headlines
|OvaScience's (OVAS) CEO Christopher Kroeger on Q4 2017 Results - Earnings Call Transcript|
seekingalpha.com - March 16 at 6:23 PM
|Edited Transcript of OVAS earnings conference call or presentation 15-Mar-18 8:30pm GMT|
finance.yahoo.com - March 16 at 6:23 PM
|HC Wainwright Reaffirms Buy Rating for OvaScience (OVAS)|
www.americanbankingnews.com - March 16 at 3:00 PM
|OvaScience Reports Fourth Quarter and Year-End 2017 Financial ... - Business Wire (press release)|
www.businesswire.com - March 16 at 8:27 AM
|OvaScience (OVAS) Posts Earnings Results, Beats Expectations By $0.04 EPS|
www.americanbankingnews.com - March 15 at 7:06 PM
|Does OvaScience Inc’s (NASDAQ:OVAS) Past Performance Indicate A Stronger Future?|
finance.yahoo.com - March 15 at 8:24 AM
|OvaScience Reports Inducement Grant Under Nasdaq Listing Rule ... - Business Wire (press release)|
www.businesswire.com - March 13 at 8:33 AM
|OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)|
finance.yahoo.com - March 12 at 6:31 PM
|OvaScience (OVAS) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - March 9 at 11:49 PM
|OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call - Business Wire (press release)|
www.businesswire.com - March 8 at 6:30 PM
|OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call|
finance.yahoo.com - March 8 at 6:30 PM
|Form 4 OvaScience, Inc. For: Mar 06 Filed by: Lillie James Woodruff - StreetInsider.com|
www.streetinsider.com - March 8 at 8:31 AM
|Zacks: Analysts Anticipate OvaScience Inc (OVAS) Will Post Quarterly Sales of $100,000.00|
www.americanbankingnews.com - February 28 at 4:48 AM
| Brokerages Anticipate OvaScience Inc (OVAS) Will Post Earnings of -$0.30 Per Share|
www.americanbankingnews.com - February 26 at 1:18 PM
|OvaScience (OVAS) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - February 21 at 2:40 AM
|Zacks: Brokerages Expect OvaScience Inc (OVAS) Will Post Quarterly Sales of $80,000.00|
www.americanbankingnews.com - February 11 at 1:48 AM
| Analysts Anticipate OvaScience Inc (OVAS) Will Announce Earnings of -$0.29 Per Share|
www.americanbankingnews.com - February 9 at 9:08 PM
|Why OvaScience Inc (NASDAQ:OVAS) Is A Financially Healthy Company|
finance.yahoo.com - February 1 at 9:57 AM
|Form 3 OvaScience, Inc. For: Jan 16 Filed by: Lillie James Woodruff - StreetInsider.com|
www.streetinsider.com - January 24 at 8:12 AM
| Brokerages Expect OvaScience Inc (OVAS) to Post -$0.29 Earnings Per Share|
www.americanbankingnews.com - January 23 at 11:06 PM
|FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018|
finance.yahoo.com - January 22 at 3:59 PM
|DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018|
finance.yahoo.com - January 18 at 11:30 AM
|OVAS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of OvaScience, Inc. Investors and Encourages Investors to ...|
www.businesswire.com - January 17 at 4:35 PM
|OVAS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of OvaScience, Inc. Investors and Encourages Investors to Contact the Firm|
finance.yahoo.com - January 17 at 4:35 PM
|Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against OvaScience, Inc. (OVAS) and Encourages Investors to Contact the Firm Before January 22, 2018|
finance.yahoo.com - January 17 at 10:18 AM
|Financial Survey: OvaScience (OVAS) vs. Chromadex (CDXC)|
www.americanbankingnews.com - January 15 at 3:32 AM
|OvaScience (OVAS) and The Competition Financial Comparison|
www.americanbankingnews.com - January 14 at 5:28 AM
|SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018|
finance.yahoo.com - January 12 at 4:25 PM
|OvaScience (OVAS) Upgraded to "Buy" by Zacks Investment Research|
www.americanbankingnews.com - January 10 at 6:00 AM
|Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against OvaScience, Inc. (OVAS) and Encourages Investors to Contact the Firm|
finance.yahoo.com - January 9 at 10:17 AM
|OvaScience Inc (OVAS) Expected to Post Quarterly Sales of $80,000.00|
www.americanbankingnews.com - January 8 at 7:02 AM
| Brokerages Expect OvaScience Inc (OVAS) Will Announce Earnings of -$0.29 Per Share|
www.americanbankingnews.com - January 6 at 7:14 PM
|Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OvaScience, Inc. - OVAS|
www.finanznachrichten.de - January 5 at 4:15 PM
|SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline – January 22, 2018|
finance.yahoo.com - January 5 at 10:34 AM
|OvaScience (OVAS) versus Its Peers Critical Survey|
www.americanbankingnews.com - January 4 at 11:06 PM
|Recros Medica Closes $9M Financing, Strengthens Board|
finance.yahoo.com - January 4 at 10:20 AM
|Announces Corporate Update - Business Wire (press release)|
www.businesswire.com - January 3 at 4:34 PM
|OvaScienceSM Announces Corporate Update|
finance.yahoo.com - January 3 at 4:34 PM
|Head to Head Review: OvaScience (OVAS) & The Competition|
www.americanbankingnews.com - January 2 at 9:14 PM
|Critical Comparison: OvaScience (OVAS) and Its Rivals|
www.americanbankingnews.com - January 1 at 3:28 AM
|OvaScience (OVAS) vs. The Competition Financial Survey|
www.americanbankingnews.com - December 31 at 10:06 PM
|Head to Head Contrast: OvaScience (OVAS) versus Its Rivals|
www.americanbankingnews.com - December 26 at 9:24 AM
|Oncobiologics (ONS) & OvaScience (OVAS) Critical Survey|
www.americanbankingnews.com - December 24 at 3:54 AM
|OvaScience Inc. (OVAS) Expected to Post Quarterly Sales of $80,000.00|
www.americanbankingnews.com - December 23 at 8:30 AM
|Analyzing OvaScience (OVAS) & Its Rivals|
www.americanbankingnews.com - December 23 at 3:07 AM
|Head-To-Head Comparison: OvaScience (OVAS) vs. The Competition|
www.americanbankingnews.com - December 21 at 9:28 AM
|Financial Review: OvaScience (OVAS) & Infinity Pharmaceuticals (INFI)|
www.americanbankingnews.com - December 20 at 11:28 AM
|IMPORTANT OVASCIENCE, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased and suffered losses in OvaScience, Inc.|
finance.yahoo.com - December 20 at 10:27 AM
|OvaScience (OVAS) and The Competition Critical Survey|
www.americanbankingnews.com - December 18 at 11:50 AM
|EQUITY ALERT: Rosen Law Firm Announces Investigation of Claims Against OvaScience, Inc.|
finance.yahoo.com - December 15 at 4:47 PM
OvaScience (NASDAQ:OVAS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OvaScience (NASDAQ:OVAS) Income Statement, Balance Sheet and Cash Flow Statement
OvaScience (NASDAQ OVAS) Stock Chart for Wednesday, March, 21, 2018